Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Non-small-cell lung carcinoma | D002289 | — | — | 19 | 73 | 13 | 6 | 15 | 109 |
Lung neoplasms | D008175 | — | C34.90 | 16 | 73 | 16 | 2 | 13 | 106 |
Small cell lung carcinoma | D055752 | — | — | 3 | 24 | 4 | 2 | 5 | 36 |
Neoplasms | D009369 | — | C80 | 9 | 21 | 1 | 1 | 1 | 29 |
Sarcoma | D012509 | — | — | 5 | 16 | 3 | 3 | 2 | 25 |
Thyroid neoplasms | D013964 | EFO_0003841 | — | — | 7 | 2 | 2 | 3 | 12 |
Thyroid diseases | D013959 | — | E00-E07 | — | 6 | 2 | 2 | 3 | 11 |
Radiotherapy | D011878 | — | — | — | 2 | — | 1 | — | 3 |
Papillary thyroid cancer | D000077273 | — | — | — | 1 | 1 | 1 | — | 2 |
Head and neck neoplasms | D006258 | — | — | — | 1 | — | 1 | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Carcinoma | D002277 | — | C80.0 | 8 | 51 | 8 | — | 4 | 63 |
Breast neoplasms | D001943 | EFO_0003869 | C50 | 2 | 18 | 1 | — | 5 | 26 |
Hepatocellular carcinoma | D006528 | — | C22.0 | 4 | 17 | 4 | — | 4 | 25 |
Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 2 | 15 | 3 | — | 4 | 22 |
Squamous cell carcinoma | D002294 | — | — | 1 | 15 | 1 | — | 1 | 16 |
Adenocarcinoma | D000230 | — | — | 4 | 11 | 1 | — | 1 | 14 |
Esophageal squamous cell carcinoma | D000077277 | — | — | — | 13 | 1 | — | 1 | 14 |
Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 2 | 10 | 2 | — | 1 | 14 |
Colorectal neoplasms | D015179 | — | — | 4 | 9 | 2 | — | — | 12 |
Ovarian epithelial carcinoma | D000077216 | — | — | 1 | 9 | 1 | — | 1 | 12 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Recurrence | D012008 | — | — | 5 | 15 | — | — | — | 16 |
Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 4 | 10 | — | — | — | 12 |
Esophageal neoplasms | D004938 | — | C15 | — | 7 | — | — | 5 | 12 |
Immunotherapy | D007167 | — | — | 1 | 6 | — | — | 1 | 7 |
Glioblastoma | D005909 | EFO_0000515 | — | 2 | 7 | — | — | — | 7 |
Brain neoplasms | D001932 | EFO_0003833 | C71 | 1 | 4 | — | — | 2 | 7 |
Gastrointestinal neoplasms | D005770 | — | C26.9 | 1 | 6 | — | — | — | 6 |
Digestive system neoplasms | D004067 | — | — | 1 | 6 | — | — | — | 6 |
Lymphoma | D008223 | — | C85.9 | — | 5 | — | — | — | 5 |
Female genital neoplasms | D005833 | — | — | 1 | 4 | — | — | 1 | 5 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Osteosarcoma | D012516 | — | — | 2 | — | — | — | — | 2 |
Liver diseases | D008107 | EFO_0001421 | K70-K77 | 1 | — | — | — | — | 1 |
Multiple myeloma | D009101 | — | C90.0 | 1 | — | — | — | — | 1 |
Plasma cell neoplasms | D054219 | — | — | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Chemoradiotherapy | D059248 | — | — | — | — | — | — | 1 | 1 |
Small cell carcinoma | D018288 | — | — | — | — | — | — | 1 | 1 |
Desmoid tumors | D018222 | — | D48.11 | — | — | — | — | 1 | 1 |
Ultrasonography | D014463 | — | — | — | — | — | — | 1 | 1 |
Colonic neoplasms | D003110 | — | C18 | — | — | — | — | 1 | 1 |
Drug common name | Catequentinib |
INN | catequentinib |
Description | Anlotinib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target vascular endothelial growth factor receptor 2, vascular endothelial growth factor receptor 3, fibroblast growth factor receptor 1, and vascular endothelial growth factor receptor 1. |
Classification | Small molecule |
Drug class | tyrosine kinase inhibitors |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1 |
PDB | — |
CAS-ID | 1058156-90-3 |
RxCUI | — |
ChEMBL ID | CHEMBL4303201 |
ChEBI ID | — |
PubChem CID | 25017411 |
DrugBank | DB11885 |
UNII ID | GKF8S4C432 (ChemIDplus, GSRS) |